The PTPRZ1-MET/STAT3/ISG20 axis in glioma stem-like cells modulates tumor-associated macrophage polarization.
Wang Y, Suo J, Wang Z, Ran K, Tian Y, Han W, Liu Y, Peng X.

Single-molecule imaging and molecular dynamics simulations reveal early activation of the MET receptor in cells.
Li Y, Arghittu SM, Dietz MS, Hella GJ, Haße D, Ferraris DM, Freund P, Barth HD, Iamele L, de Jonge H, Niemann HH, Covino R, Heilemann M., Free PMC Article

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.
Reale ML, Passiglia F, Cappuzzo F, Minuti G, Occhipinti M, Bulotta A, Delmonte A, Sini C, Galetta D, Roca E, Pelizzari G, Cortinovis D, Gariazzo E, Pilotto S, Citarella F, Bria E, Muscolino P, Pozzessere D, Carta A, Pignataro D, Calvetti L, Leone F, Banini M, Di Micco C, Baldini E, Favaretto A, Malapelle U, Novello S, Pasello G, Tiseo M., Free PMC Article

Differential Immune Checkpoint Protein Expression in HNSCC: The Role of HGF/MET Signaling.
Boschert V, Boenke J, Böhm AK, Teusch J, Steinacker V, Straub A, Hartmann S., Free PMC Article

PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.
Jing N, Du X, Liang Y, Tao Z, Bao S, Xiao H, Dong B, Gao WQ, Fang YX., Free PMC Article

Deregulated immune cell recruitment orchestrated by c-MET impairs pulmonary inflammation and fibrosis.
Barbosa-Matos C, Borges-Pereira C, Libório-Ramos S, Fernandes R, Oliveira M, Mendes-Frias A, Silvestre R, Osório NS, Bastos HN, Santos RF, Guimarães S, Morais A, Mazzone M, Carvalho A, Cunha C, Costa S., Free PMC Article

Spatiotemporal regulation of the hepatocyte growth factor receptor MET activity by sorting nexins 1/2 in HCT116 colorectal cancer cells.
Garcia Delgado L, Derome A, Longpré S, Giroux-Dansereau M, Basbous G, Lavoie C, Saucier C, Denault JB., Free PMC Article

MET alterations in advanced non-small cell lung cancer.
Chagas GCL, Rangel AR, El Osta B.

MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study.
Wang N, Zhang Y, Wu J, Zhu Y, Wu Y, Huang B, Zhang R, Fan J, Nie X.

Clinical, pathologic, and genomic characteristics of two pediatric glioneuronal tumors with a CLIP2::MET fusion.
Chapman N, Greenwald J, Suddock J, Xu D, Markowitz A, Humphrey M, Cotter JA, Krieger MD, Hawes D, Ji J., Free PMC Article

Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target.
Chauhan S, Sen S, Irshad K, Kashyap S, Pushker N, Meel R, Sharma MC.

MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.
Riedel R, Fassunke J, Scheel AH, Scheffler M, Heydt C, Nogova L, Michels S, Fischer RN, Eisert A, Scharpenseel H, John F, Ruge L, Schaufler D, Siemanowski J, Ihle MA, Wagener-Ryczek S, Pappesch R, Rehker J, Bunck A, Kobe C, Keil F, Merkelbach-Bruse S, Büttner R, Wolf J.

Up-regulation by overexpression of c-MET in fibroblastic foci of usual interstitial pneumonia.
Melocchi L, Cervi G, Sartori G, Gandolfi L, Jocollé G, Cavazza A, Rossi G., Free PMC Article

[Chinese expert consensus on MET immunohistochemistry detection and interpretation standards for non-small cell lung cancer(2023 version)].
Standardization Interpretation Expert Committee of MET immunohistochemistry, Molecular Pathology Collaboration Group of Tumor Pathology Committee of Chinese Anti-Cancer Association.

Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.
Skribek M, Brunnström H, Oskarsdottir G, Portu Grivé M, Aricak O, Planck M, Jatta K, Naserhojati H, Haglund de Flon F, Ekman S.

Role of hypoxia on microRNA-dependant regulation of HGFA - HGF - c-Met signalling pathway in human progenitor and mature endothelial cells.
Tokarski M, Cierzniak A, Baczynska D.

PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target.
Singh S, Yeat NY, Wang YT, Lin SY, Kuo IY, Wu KP, Wang WJ, Wang WC, Su WC, Wang YC, Chen RH., Free PMC Article

c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.
Huo Q, Lv J, Zhang J, Huang H, Hu H, Zhao Y, Zhang X, Wang Y, Zhou Y, Qiu J, Ye Y, Huang A, Chen Y, Qin L, Qin D, Li P, Cai G.

HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met.
Ma H, Wei W, Liang D, Xu X, Yang D, Wang Q, Wang Y, Wei Q, Sun B, Zhao X.

c-Met activation promotes extravasation of hepatocellular carcinoma cells into 3D-cultured hepatocyte cells in lab-on-a-chip device.
Bagci G, Comez D, Topel H, Yilmaz Y, Bagirsakci E, Gunes A, Batı Ayaz G, Tahmaz I, Bilgen M, Solmaz G, Pesen Okvur D, Atabey N.

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J, Vioix H, Pfeiffer BM, Campden RI, Chen Z, Heeg B, Cortot AB.

Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer.
Lang L, Chen F, Li Y, Shay C, Yang F, Dan H, Chen ZG, Saba NF, Teng Y., Free PMC Article

Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis.
Zhou Y, Cui G, Xu H, Chun J, Yang D, Zhang Z, Yang L, Wang J, Wan M, Calvisi DF, Lin S, Chen X, Wang H., Free PMC Article

Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites.
Burgess EF, Livasy CA, Symanowski JT, Matulay JT, Grigg CM, Clark PE, Raghavan D.

Molecular characterization of MET fusions from a large real-world Chinese population: A multicenter study.
Xia H, Zhang J, Chen T, Wang M, Chen D, Si T, Liu Y., Free PMC Article